AMENDMENTS TO THE CLAIMS

This listing of the claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-13 (**Cancelled**).

14. (**Currently amended**) A method of preparing a bioabsorbable synthetic nonwoven fabric holding thrombin and fibrinogen as effective ingredients, and enabling hemostasis comprising suppressing loss of blood in a patient in need thereof, comprising ~~either~~

[[(1)]] immersing a bioabsorbable synthetic nonwoven fabric made of polyglycolic acid into a saline or buffer solution containing thrombin and lyophilizing, and then immediately prior to use thereof, applying fibrinogen to said nonwoven fabric containing thrombin; [[or]]

~~(2) immediately prior to use, sequentially applying thrombin and fibrinogen onto a bioabsorbable synthetic nonwoven fabric made of polyglycolic acid;~~

so that said thrombin and said fibrinogen are separated from each other and will not react with one another before use thereof;

wherein the ~~bioabsorable~~ bioabsorbable synthetic nonwoven fabric of polyglycolic acid is a needle-punched and elastic polyglycolic acid fabric; and

said method is capable of ~~preventing recurrent bleeding, projectile bleeding and~~ ceasing exudative bleeding after initial bleeding, with a single hemostatic treatment.

Claims 15-16 (**Cancelled**).

17. (**Previously Presented**) The method according to claim 14, wherein said hemostatic material comprises at least one additive selected from Factor XIII, a protease inhibitor, or calcium chloride.

18. (**Previously presented**) The method according to claim 17, wherein said calcium chloride is fixed to the bioabsorbable synthetic nonwoven fabric together with thrombin.

19. (**Previously presented**) The method according to claim 17, wherein said Factor XIII is added to fibrinogen.

20. (**Previously presented**) The method according to claim 17, wherein said thrombin, fibrinogen and Factor XIII are either derived from human blood or produced by a genetic recombination technique.

21. (**Currently amended**) A hemostatic kit consisting of

a bioabsorbable synthetic nonwoven needle-punched and elastic fabric made of polyglycolic acid holding thrombin as an effective ingredient,

a container comprising fibrinogen as an effective ingredient,

wherein the fibrinogen is capable of being added to the bioabsorbable synthetic nonwoven needle-punched and elastic fabric holding thrombin, and

optionally at least one additive; and

wherein said fabric, when holding both thrombin and fibrinogen, is capable of preventing ~~recurrent bleeding, projectile bleeding and~~ ceasing exudative bleeding after initial bleeding with a single hemostatic treatment.

Claims 22-23 (**Cancelled**).

24. (**Previously Presented**) The hemostatic kit according to claim 21, wherein said hemostatic kit comprises said at least one additive selected from Factor XIII, a protease inhibitor, or calcium chloride.

25. (**Original**) The hemostatic kit according to claim 24, wherein said calcium chloride is added to the bioabsorbable synthetic nonwoven fabric as an additive for thrombin.

26. (**Previously presented**) The hemostatic kit according to claim 24, wherein said Factor XIII is included in a container comprising fibrinogen.

27. (**Previously presented**) The hemostatic kit according to claim 24, wherein said thrombin, fibrinogen and Factor XIII are either derived from human blood or produced by a genetic recombination technique.

28. (**Previously presented**) The hemostatic kit according to claim 21, wherein said bioabsorbable synthetic nonwoven fabric holding thrombin is prepared by the steps of immersing a bioabsorbable synthetic nonwoven fabric into a solution containing thrombin and of lyophilizing the obtained nonwoven fabric.

29. (**Currently amended**) A hemostatic kit consisting of

a bioabsorbable synthetic nonwoven needle-punched and elastic fabric made of polyglycolic acid as a substrate,

a container comprising thrombin as an effective ingredient,

a container comprising fibrinogen as an effective ingredient, and

optionally at least one additive; and

wherein, when fibrinogen and thrombin are added to the bioabsorbable non-woven needle-punched and elastic fabric, said fabric holding thrombin and fibrinogen is capable of ~~preventing recurrent bleeding, projectile bleeding and~~ ceasing exudative bleeding after initial bleeding with a single hemostatic treatment.

Claims 30-31 (**Cancelled**).

32. (**Previously Presented**) The hemostatic kit according to claim 29, wherein said hemostatic kit comprises said at least one additive selected from Factor XIII, a protease inhibitor, or calcium chloride.

33. (**Original**) The hemostatic kit according to claim 32, wherein said Factor XIII is included in a container comprising fibrinogen.

34. (**Previously presented**) The hemostatic kit according to claim 32, wherein said thrombin, fibrinogen and Factor XIII are either derived from human blood or produced by a genetic recombination technique.

Claims 35-40 (**Cancelled**).

41. **(Currently Amended)** The method of claim 14, further comprising applying the bioabsorbable synthetic nonwoven fabric holding thrombin and fibrinogen against a wound suffering ~~projectile~~ exudative bleeding, after initial bleeding.